Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.
Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N. Marchica V, et al. Among authors: bolzoni m. Cancers (Basel). 2019 Mar 6;11(3):321. doi: 10.3390/cancers11030321. Cancers (Basel). 2019. PMID: 30845779 Free PMC article.
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.
Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F. Morandi F, et al. Among authors: bolzoni m. Oncoimmunology. 2018 May 7;7(8):e1458809. doi: 10.1080/2162402X.2018.1458809. eCollection 2018. Oncoimmunology. 2018. PMID: 30221054 Free PMC article.
Possible targets to treat myeloma-related osteoclastogenesis.
Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N. Bolzoni M, et al. Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Expert Rev Hematol. 2018. PMID: 29495905 Review.
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.
Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein AL, Aversa F, Malavasi F, Giuliani N. Costa F, et al. Among authors: bolzoni m. Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915615 Free PMC article.
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.
Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N. Costa F, et al. Among authors: bolzoni m. Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881793 Free PMC article.
39 results